CC-312 in Idiopathic Inflammatory Myopathies: NCT07193810 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 15 October 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Early Phase 1
Clinical phase
Recruiting
Recruitment status
not reported
Planned enrollment
2027-09-29
Primary-completion proxy
Executive view
NCT07193810 evaluates CC-312 in Idiopathic Inflammatory Myopathies. The disclosed sponsor is CytoCares Shanghai, Inc., the design is Interventional, and the geographic footprint is China. The first listed primary endpoint is Dose-limiting toxicity (DLT), assessed over 2 years.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07193810 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Idiopathic Inflammatory Myopathies landscape. Drug & Asset MCP drug_fetch was queried for CC-312, while Company & Deal Intelligence MCP organization_fetch was queried for CytoCares Shanghai, Inc..
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07193810 | CC-312 | Early Phase 1 / Recruiting | CytoCares Shanghai, Inc. | China | Dose-limiting toxicity (DLT) 2 years | 2027-09-29 |
| NCT07193667 | CD19 CAR-T cells(ShenZhen Cell Valley) | Not Applicable / Recruiting | Cell Valley Inc. | China | chimeric status 1 year after transplantation | 2027-09-01 |
| NCT07185269 | Recombinant anti-BDCA2 humanized monoclonal antibody(Sunshine Guojian) | Phase 1/2 / Recruiting | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | China | Number of participants with Adverse Events During the 32- or 36-week study period | 2028-08-12 |
| NCT07177911 | CC-312 | Phase 1 / Recruiting | CytoCares Shanghai, Inc. | China | Adverse events (AE)/serious adverse events (SAE) 2 years | 2027-09-10 |
| NCT07174843 | BZE-2204 | Early Phase 1 / Recruiting | Shanghai Cell Therapy Group Co., Ltd. | China | The frequency and severity of adverse events(AE) and serious adverse events(SAE) From leukapheresis to 6 months post CAR-T infusion | 2027-08-01 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07193810 is a Early Phase 1, recruiting study with not reported planned participants. Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment.
The primary endpoint is “Dose-limiting toxicity (DLT)” over “2 years.” The retrieved endpoint description is: A Dose-Limiting Toxicity (DLT) is defined as any adverse event occurring within the 29-day period following the initiation of CC312 intravenous infusion during the dose-escalation phase, assessed by the investigator as related to CC312 and meeting the following criteria: (1) Hematologic Toxicity: Grade 4 toxicity (excluding lymphopenia) persisting beyond 29 days and not attributable to underlying disease; (2) Non-Hematologic Toxicity: Any ≥Grade 4 toxicity potentially related to CC312 during the observation window, or any Grade 3 toxicity potentially related to CC312 that fails to resolve to ≤Grade 2 within 7 da….
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of not reported should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
0 recent result records were selected as contextual evidence for Idiopathic Inflammatory Myopathies. These records do not establish direct evidence for NCT07193810 unless the registration number matches.
Indexed evidence status
No directly comparable result record was retrieved for this disease query. This is a monitoring gap, not evidence of absence.
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
CC-312 is indexed as Trispecific T-cell engager (TriTE) with CD19 x CD28 x CD3 biology and a global stage of Phase 1. The asset profile lists CytoCares Shanghai, Inc. as an originator or developer.
CytoCares Shanghai, Inc. is indexed in an unreported country with the website http://www.cytocares.com. Cytocares offers innovative drug design for antibody novel medication creation and development in the realm of tumor immunity. The record lists 2 development-stage drug assets.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether CC-312 is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07193810
Protocol source: https://clinicaltrials.gov/study/NCT07193810
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 15 October 2026.
CC-312 in Idiopathic Inflammatory Myopathies is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Dose-limiting toxicity (DLT) and 2027-09-29 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
